Trends in US Hospital Admissions for Skin and Soft Tissue Infections

John Edelsberg, Charu Taneja, Marcus Zervos, Nadia Haque, Carol Moore, Katherine Reyes, James Spalding, Jenny Jiang, and Gerry Oster

Using data from the 2000–2004 US Healthcare Cost and Utilization Project National Inpatient Sample, we found that total hospital admissions for skin and soft tissue infections increased by 29% during 2000–2004; admissions for pneumonia were largely unchanged. These results are consistent with recent reported increases in community-associated methicillin-resistant *Staphylococcus aureus* infections.

During 1998–2004, *Staphylococcus aureus* was the most common cause of skin and soft tissue infections (SSTIs) in North America; frequency of these infections was 44.6%, and the rate of methicillin resistance among the isolates was 35.9% (1). Over the past decade, community-associated methicillin-resistant *S. aureus* (CA-MRSA) has become a notable public health problem; it accounts for 14% of invasive infections nationwide and 59% (range 15%–74%) of SSTIs among patients seeking treatment at emergency departments in 11 US cities (2,3). The emergence of CA-MRSA infections may have resulted in increased numbers of hospitalizations for SSTIs because of an increasing incidence of antimicrobial drug failure in outpatient treatment and more aggressive approaches to the management of these infections by physicians who are aware of the heightened risk of becoming infected with CA-MRSA. To determine whether hospital admissions for CA-MRSA are increasing, we analyzed data from the Healthcare Cost and Utilization Project National Inpatient Sample.

Using data from the 2000–2004 US Healthcare Cost and Utilization Project National Inpatient Sample, we found that total hospital admissions for skin and soft tissue infections increased by 29% during 2000–2004; admissions for pneumonia were largely unchanged. These results are consistent with recent reported increases in community-associated methicillin-resistant *Staphylococcus aureus* infections.

**The Study**

This study was based on data from the Healthcare Cost and Utilization Project National Inpatient Sample (HCUP NIS) for the 5-year period 2000–2004. HCUP NIS is a stratified random sample from >20% of all US community hospitals. For 2004, the NIS contains all discharge data from >1,000 acute-care hospitals in 37 states, representing >8 million hospital stays.

We identified all hospital admissions in the HCUP NIS for which a principal diagnosis of SSTI was given. As defined by the Uniform Hospital Discharge Data Set, principal diagnosis is the condition “established after study to be chiefly responsible for occasioning the admission of the patient to the hospital for care” (http://wonder.cdc.gov).

SSTIs were defined as the following: 1) acute lymphadenitis (International Classification of Diseases, 9th Revision, Clinical Modification [ICD-9-CM] 683.XX); 2) carbuncle and furuncle (680.XX); 3) cellulitis and abscess of finger and toe (681.XX); 4) impetigo (684.XX); 5) infection (chronic) of amputation stump (997.62); 6) other cellulitis and abscess (682.XX); 7) other local infections of skin and subcutaneous tissue (686.XX); 8) abscess of anal and rectal regions (566); 9) chronic ulcer of other specified sites (707.8); 10) chronic ulcer of unspecified site (707.9); 11) decubitus ulcer (707); 12) infection due to other vascular device implant and graft (996.62); 13) pilonidal cyst with abscess (685); 14) postoperative wound infection (998.5X); 15) posttraumatic wound infection, not elsewhere classified (958.3); 16) ulcers of lower limbs, except decubitus (707.1X); 17) gangrene (785.4); and 18) necrotizing fascitis (728.86).

To aid in interpretation of the data, we grouped the above-listed SSTIs into 3 mutually exclusive categories: 1) superficial infections predominantly caused by *S. aureus* or *Streptococcus pyogenes* (groups 1–7 above); 2) deeper or healthcare-associated infections more likely to involve anaerobic or gram-negative organisms (groups 8–16); and 3) infections typically associated with a high rate of mortality (groups 17–18). For each year of interest, all SSTI admissions were then stratified by type of infection and selected patient and hospital characteristics.

To provide a benchmark against which to interpret possible trends in SSTI-related hospital admissions, we generated similar series for all admissions with a principal diagnosis of infectious pneumonia, another common type of infection that frequently results in hospitalization but for which no trends were expected. Infectious pneumonia was defined to include 1) pneumococcal pneumonia (ICD-9-CM 481); 2) other bacterial pneumonia (482.XX).

**Table 1. Estimated total number of US hospital admissions for SSTIs and infectious pneumonia, 2000–2004**

<table>
<thead>
<tr>
<th>Principal diagnosis</th>
<th>2000</th>
<th>2001</th>
<th>2002</th>
<th>2003</th>
<th>2004</th>
<th>Change from 2000 to 2004</th>
</tr>
</thead>
<tbody>
<tr>
<td>SSTI</td>
<td>674,939</td>
<td>701,672</td>
<td>757,858</td>
<td>810,768</td>
<td>869,777</td>
<td>194,838 (+28.9%)</td>
</tr>
<tr>
<td>Infectious pneumonia</td>
<td>1,202,387</td>
<td>1,177,972</td>
<td>1,229,204</td>
<td>1,272,686</td>
<td>1,172,304</td>
<td>-30,083 (−2.5%)</td>
</tr>
</tbody>
</table>

### Table 2. Number of hospital admissions with principal diagnosis of SSTI, by patient and infection characteristics and year*

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Race†</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>364,634 (54.0)</td>
<td>368,901 (52.6)</td>
<td>372,013 (49.1)</td>
<td>409,037 (50.5)</td>
<td>439,295 (50.5)</td>
</tr>
<tr>
<td>Black</td>
<td>81,654 (12.1)</td>
<td>81,299 (11.6)</td>
<td>94,307 (12.4)</td>
<td>99,892 (12.3)</td>
<td>111,416 (12.8)</td>
</tr>
<tr>
<td>Hispanic/Latino</td>
<td>57,217 (8.5)</td>
<td>59,345 (8.5)</td>
<td>63,657 (8.4)</td>
<td>78,091 (9.6)</td>
<td>75,142 (8.6)</td>
</tr>
<tr>
<td>Asian or Pacific Islander</td>
<td>6,457 (1.0)</td>
<td>7,219 (1.0)</td>
<td>8,496 (1.1)</td>
<td>9,366 (1.2)</td>
<td>10,053 (1.2)</td>
</tr>
<tr>
<td>Native American</td>
<td>2,082 (0.3)</td>
<td>2,375 (0.3)</td>
<td>2,211 (0.3)</td>
<td>1,595 (0.2)</td>
<td>3,890 (0.5)</td>
</tr>
<tr>
<td>Other</td>
<td>11,873 (1.8)</td>
<td>11,233 (1.6)</td>
<td>16,304 (2.2)</td>
<td>14,135 (1.7)</td>
<td>13,937 (1.6)</td>
</tr>
<tr>
<td><strong>Infection type (ICD-9-CM diagnosis code[s])</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Superficial infections</td>
<td>390,158 (57.8)</td>
<td>404,536 (57.7)</td>
<td>440,501 (58.1)</td>
<td>479,222 (59.1)</td>
<td>520,099 (59.8)</td>
</tr>
<tr>
<td>Acute lymphadenitis (683.XX)</td>
<td>4,570 (0.7)</td>
<td>4,341 (0.6)</td>
<td>4,230 (0.6)</td>
<td>4,324 (0.5)</td>
<td>4,291 (0.5)</td>
</tr>
<tr>
<td>Carbuncle and furuncle (680.XX)</td>
<td>1,001 (0.2)</td>
<td>1,182 (0.2)</td>
<td>1,349 (0.2)</td>
<td>1,900 (0.2)</td>
<td>2,298 (0.3)</td>
</tr>
<tr>
<td>Cellulitis and abscess of finger and toe (681.XX)</td>
<td>20,060 (3.0)</td>
<td>20,868 (3.0)</td>
<td>22,731 (3.0)</td>
<td>25,174 (3.1)</td>
<td>27,833 (3.2)</td>
</tr>
<tr>
<td>Impetigo (684.XX)</td>
<td>1,221 (0.2)</td>
<td>1,084 (0.2)</td>
<td>1,250 (0.2)</td>
<td>1,337 (0.2)</td>
<td>1,481 (0.2)</td>
</tr>
<tr>
<td>Infection (chronic) of amputation stump (997.62)</td>
<td>13,431 (2.0)</td>
<td>14,874 (2.1)</td>
<td>15,100 (2.0)</td>
<td>14,459 (1.8)</td>
<td>16,014 (1.8)</td>
</tr>
<tr>
<td>Other cellulitis and abscess (682.XX)</td>
<td>346,270 (51.3)</td>
<td>358,884 (51.2)</td>
<td>392,422 (51.8)</td>
<td>428,274 (52.8)</td>
<td>464,016 (53.4)</td>
</tr>
<tr>
<td>Other local infections of skin (686.XX)</td>
<td>3,605 (0.5)</td>
<td>3,302 (0.5)</td>
<td>3,419 (0.5)</td>
<td>3,755 (0.5)</td>
<td>4,167 (0.5)</td>
</tr>
<tr>
<td>Deeper and/or healthcare-associated infections</td>
<td>274,549 (40.7)</td>
<td>287,736 (41.0)</td>
<td>307,300 (40.6)</td>
<td>320,580 (39.5)</td>
<td>339,337 (39.0)</td>
</tr>
<tr>
<td>Abscess of anal and rectal region (566)</td>
<td>20,511 (3.0)</td>
<td>20,273 (2.9)</td>
<td>22,772 (3.0)</td>
<td>23,892 (3.0)</td>
<td>24,655 (2.8)</td>
</tr>
<tr>
<td>Chronic ulcer of other specified sites (707.8)</td>
<td>132 (0.0)</td>
<td>75 (0.0)</td>
<td>73 (0.0)</td>
<td>68 (0.0)</td>
<td>62 (0.0)</td>
</tr>
<tr>
<td>Chronic ulcer of unspecified site (707.9)</td>
<td>2,136 (0.3)</td>
<td>2,191 (0.3)</td>
<td>2,389 (0.3)</td>
<td>2,666 (0.3)</td>
<td>2,465 (0.3)</td>
</tr>
<tr>
<td>Decubitus ulcer (707.0)</td>
<td>37,116 (5.5)</td>
<td>38,637 (5.5)</td>
<td>36,816 (4.9)</td>
<td>38,167 (4.7)</td>
<td>39,706 (4.6)</td>
</tr>
<tr>
<td>Infection due to vascular device (996.62)</td>
<td>64,262 (9.5)</td>
<td>73,051 (10.4)</td>
<td>78,289 (10.3)</td>
<td>81,970 (10.1)</td>
<td>91,804 (10.6)</td>
</tr>
<tr>
<td>Pilonidal cyst with abscess (685.0)</td>
<td>2,262 (0.3)</td>
<td>2,167 (0.3)</td>
<td>2,447 (0.3)</td>
<td>2,496 (0.3)</td>
<td>2,604 (0.3)</td>
</tr>
<tr>
<td>Postoperative wound infection (998.5X)</td>
<td>115,694 (17.1)</td>
<td>120,344 (17.2)</td>
<td>134,783 (17.8)</td>
<td>138,393 (17.1)</td>
<td>144,768 (16.6)</td>
</tr>
<tr>
<td>Posttraumatic wound infection, NEC (958.3)</td>
<td>2,748 (0.4)</td>
<td>2,239 (0.3)</td>
<td>1,664 (0.2)</td>
<td>2,326 (0.3)</td>
<td>2,843 (0.3)</td>
</tr>
<tr>
<td>Ulcers of lower limbs, except decubitus (707.1X)</td>
<td>29,688 (4.4)</td>
<td>28,759 (4.1)</td>
<td>28,067 (3.7)</td>
<td>30,602 (3.8)</td>
<td>30,431 (3.5)</td>
</tr>
<tr>
<td>Often fatal infections</td>
<td>10,232 (1.5)</td>
<td>9,400 (1.3)</td>
<td>10,057 (1.3)</td>
<td>10,965 (1.4)</td>
<td>10,341 (1.2)</td>
</tr>
<tr>
<td>Gangrene (785.4)</td>
<td>5,628 (0.8)</td>
<td>4,814 (0.7)</td>
<td>5,155 (0.7)</td>
<td>5,546 (0.7)</td>
<td>4,331 (0.5)</td>
</tr>
<tr>
<td>Necrotizing fasciitis (728.86)</td>
<td>4,604 (0.7)</td>
<td>4,586 (0.7)</td>
<td>4,902 (0.7)</td>
<td>5,419 (0.7)</td>
<td>6,010 (0.7)</td>
</tr>
</tbody>
</table>

*SSFI, skin and soft tissue infection; ICD-9-CM, International Classification of Diseases, 9th Revision, Clinical Modification; NEC, not elsewhere classified. Numbers are given as no. (%); admissions; N values for each year are provided. Source: Healthcare Cost and Utilization Project National Inpatient Sample, 2000–2004.
†Percentages may not add up to 100% due to missing data.
unchanged. We are unaware of any other data to which our
2004, admissions for infectious pneumonia were largely
hospital characteristics (e.g., urban vs. rural) available
the HCUP NIS. For comparison, we also examined total
hospital admissions for infectious pneumonia.
Because the HCUP NIS undergoes periodic changes in
its sampling frame and weighting method, as well as in data
and definitions, we used the NIS Trends Supplemental (NIS-Trends) files to ensure comparability of data
across the years of interest. The NIS-Trends files contain
sampling weights and data elements that are consistently
defined across all years of interest.
Analyses were primarily descriptive (i.e., no a priori
hypotheses were made, and our results were not subjected
to formal significance testing). All analyses were conducted
by using the SAS Proprietary Software, Release 9.1 (SAS
Institute, Cary, NC, USA).
The estimated total number of annual SSTI admissions
to US acute-care hospitals rose steadily over the 5-year pe-
period, from 675,000 in 2000 to 869,800 in 2004, an increase
of 194,000 (29%) admissions. In contrast, total admissions
for infectious pneumonia fluctuated from year to year and
were largely unchanged over this period (Table 1).
The increase in SSTI admissions was greatest among
younger (age <65 years) rather than older patients (age 65–
100 years) (37% vs. 14%, respectively) and for urban rather
than rural hospitals (32% vs. 11%) (Table 2). The increase
in SSTI admissions also was greatest among patients with
superficial infections (e.g., cellulitis, abscess) rather than
deeper or healthcare-associated infections (e.g., postop-
erative wound infection, infection due to vascular device)
(33% vs. 24%).

Conclusions
Until recently, CA-MRSA was relatively uncommon.
In 2000, for example, these isolates accounted for only 3%
of staphylococcal isolates submitted to Minnesota laborato-
ries (4). In recent years, however, CA-MRSA has become
a major cause of SSTIs. The prevalence of MRSA among
patients with SSTIs who sought treatment at 1 Los Angeles
area emergency department increased from 29% in 2001 to
64% in 2004 (5).
While the estimated total number of SSTI admissions
to US acute-care hospitals increased by ≈29% during 2000–
2004, admissions for infectious pneumonia were largely
unchanged. We are unaware of any other data to which our
findings might be directly compared. Our results appear
to be consistent, however, with those of previous studies
that have reported an increasing prevalence of illness
attributable to S. aureus infections in general and to MRSA
in particular (6,7). Although we could not establish in our
study whether the increase in the number of SSTI hospital
admissions was a result of the growing prevalence of
CA-MRSA (the HCUP-NIS does not report microbiologic
data), we suspect that the 2 phenomena are closely linked—
especially in light of the absence of any similar increase
in hospital admissions for pneumonia, the most common
community-associated infection requiring hospitalization.
We therefore believe that the clinical and economic effects
of CA-MRSA SSTIs are substantial and growing, and that
this increase should be a focus of additional research.

Funding for this research was provided by Astellas Pharma
US, Inc. Although the study sponsor participated in discussions
concerning the design and conduct of the study, manuscript
preparation, and the decision to submit the manuscript for publication,
all final decisions were made by the authors.

Dr Edelsberg is medical director at Policy Analysis Inc., in
Brookline, MA, USA, and a former instructor and Director of Research
in Emergency Medicine at the University of Massachusetts
Medical School. His research interests are the cost and epidemiol-
ogy of chronic diseases.

References
1. Moet GJ, Jones RN, Biedenbach DJ, Stilwell MG, Fritsche TR. Contemporary
causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial
Jama.298.15.1763
3. Moran GJ, Krishnadasan A, Gorwitz RJ, Fosheim GE, McDou-
2006;355:666–74. DOI: 10.1056/NEJMoa055356
4. Naimi TS, LeDell KH, Boxrud DJ, Groom AV, Steward CD, Johnson
Clin Infect Dis. 2001;33:990–6. DOI: 10.1086/322693
5. Moran GJ, Amri RN, Abrahamian FM, Talan DA. Methicillin-resis-
6. Noskin GA, Rubin RJ, Schentag JJ, Kluymans J, Hedblom EC, Jacob-
on C, et al. National trends in Staphylococcus aureus infection rates: impact on economic burden and mortality over a 6-year pe-
caused by methicillin-resistant Staphylococcus aureus, United

Address for correspondence: Gerry Oster, Policy Analysis Inc., 4 Davis
Ct, Brookline, MA 02445, USA; email: goster@pai2.com